Related Experiment Video

Updated: Jul 20, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Measures of thrombosis and fibrinolysis

Brian G Choi1, Gemma Vilahur, Borja Ibanez

  • 1Cardiovascular Biology Research Laboratory, Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1030, New York, NY 10029, USA.

Clinics in Laboratory Medicine
|August 30, 2006
PubMed

Insights

Markers for thrombosis and fibrinolysis show promise for predicting cardiovascular heart disease risk. However, inconsistent lab methods hinder routine clinical use of these important acute coronary syndrome markers.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Clinical Chemistry

Background:

  • Acute coronary syndrome is understood as an atherothrombotic process.
  • Research focuses on thrombosis and fibrinolysis markers for cardiovascular heart disease risk prediction.
  • Current guidelines suggest fibrinogen, factor VII, PAI-1, t-PA, and vWF as potentially useful markers.

Purpose of the Study:

  • To review the development and clinical utility of thrombosis and fibrinolysis markers for cardiovascular risk prediction.
  • To address challenges in the routine clinical application of these markers.
  • To provide guidance on laboratory handling, evidence of accuracy, and current clinical use.

Main Methods:

  • Review of historical development of thrombosis and fibrinolysis assays.
  • Analysis of laboratory methodologies and their impact on result interpretation.
  • Evaluation of clinical trial data supporting the accuracy of these markers.
  • Examination of current American Heart Association/American College of Cardiology guidelines.

Main Results:

  • Despite recommendations, thrombosis and fibrinolysis markers are not in routine clinical use.
  • Inconsistent laboratory methodology is a significant barrier to comparing results and clinical interpretation.
  • Evidence supporting the accuracy of these markers exists but is hampered by methodological variability.

Conclusions:

  • Thrombosis and fibrinolysis markers have potential for cardiovascular risk stratification.
  • Standardization of laboratory methods is crucial for their effective clinical implementation.
  • Further research and guideline updates are needed to facilitate routine use of these predictive markers.

More Related Videos

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...